Regentis (RGNT) Director Ben‑Elazar Receives Option Grants

What Happened

• Ben‑Elazar Pini, a director of Regentis Biomaterials Ltd. (RGNT), was granted a total of 33,139 stock options in two awards on July 9, 2026: 24,826 options and 8,313 options. Both grants are reported as derivative awards with a reported cash price of $0.00 (i.e., no cash exchanged on grant). No exercise or sale of shares was reported in this filing.

Key Details

• Transaction date(s): July 9, 2026 (reported on Form 4 filed July 13, 2026).
• Grants: 24,826 options (Grant A) and 8,313 options (Grant B); combined = 33,139 options.
• Reported price/value: $0.00 per option on grant (no cash paid).
• Vesting:
  • The 24,826‑option grant was approved by the board on June 4, 2026 and became effective upon shareholder approval on July 9, 2026; it vests quarterly with 1/12 vesting on Sept 4, 2026 and then one‑twelfth every three months thereafter, fully vesting on June 4, 2029 (3‑year schedule).
  • The 8,313‑option grant was approved Feb 23, 2026 and subject to shareholder approval (obtained July 9, 2026); this grant is reported as fully vested as of the filing date.
• Shares owned after transaction: not specified in the provided filing details.
• Tax/trustee note: To qualify for certain Israeli tax benefits (Sec. 102 of the Israeli Tax Ordinance), securities issued under the 2024 Share Option Plan must be registered in the name of a trustee.
• Timeliness: Form 4 was filed July 13, 2026 for transactions on July 9, 2026 (filed within the standard two business‑day window).

Context

• These are option awards (derivative grants), not open‑market purchases or sales. The filing does not report any exercise or sale of the options or any immediate sale of underlying shares.
• Option grants are common for directors and employees as compensation; they represent potential future equity if vested and exercised. Because one grant is fully vested, those options could be exercisable subject to plan terms, but no exercise was reported here.